Literature DB >> 25170641

Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.

David Benjamin Shultz1, Andrea Riccardo Filippi, Juliette Thariat, Francoise Mornex, Billy W Loo, Umberto Ricardi.   

Abstract

An increasing body of experience suggests that oligometastasis represents a minimal metastatic state with the potential for cure or prolonged survival in selected patients treated with radical local therapy to all identified sites of disease. The main clinical scenarios managed by thoracic oncology specialists are pulmonary oligometastases from primary malignancies of other anatomic sites and primary lung cancer with oligometastases to lung or other organs. Surgery has been a mainstay of treatment in these situations, with remarkably favorable outcomes following pulmonary metastasectomy in well-selected patient cohorts. As with early stage lung cancer in patients who are medically inoperable, stereotactic ablative radiotherapy is emerging as a prominent local treatment option for oligometastatic disease. We review the role and clinical experience of stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.

Entities:  

Mesh:

Year:  2014        PMID: 25170641     DOI: 10.1097/JTO.0000000000000317

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  22 in total

1.  A phase I/II study on stereotactic body radiotherapy with real-time tumor tracking using CyberKnife based on the Monte Carlo algorithm for lung tumors.

Authors:  Hiromitsu Iwata; Satoshi Ishikura; Taro Murai; Michio Iwabuchi; Mitsuhiro Inoue; Koshi Tatewaki; Seiji Ohta; Naoki Yokota; Yuta Shibamoto
Journal:  Int J Clin Oncol       Date:  2017-04-20       Impact factor: 3.402

Review 2.  Emerging Treatment Paradigms in Radiation Oncology.

Authors:  Quynh-Thu Le; Hiroki Shirato; Amato J Giaccia; Albert C Koong
Journal:  Clin Cancer Res       Date:  2015-05-19       Impact factor: 12.531

3.  Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

Authors:  Suchit H Patel; Andreas Rimner; Amanda Foster; Zhigang Zhang; Kaitlin M Woo; Helena A Yu; Gregory J Riely; Abraham J Wu
Journal:  Lung Cancer       Date:  2017-03-24       Impact factor: 5.705

4.  Role of consolidative stereotactic ablative radiotherapy in patients with oligometastatic non-small cell lung cancer.

Authors:  Umberto Ricardi; Niccolò Giaj Levra; Serena Badellino; Filippo Alongi
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

5.  Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours.

Authors:  Davide Franceschini; Luca Cozzi; Fiorenza De Rose; Piera Navarria; Ciro Franzese; Tiziana Comito; Cristina Iftode; Angelo Tozzi; Lucia Di Brina; Anna Maria Ascolese; Elena Clerici; Giuseppe D'Agostino; Antonella Fogliata; Marta Scorsetti
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-03       Impact factor: 4.553

6.  Application of real-time MRI-guided linear accelerator in stereotactic ablative body radiotherapy for non-small cell lung cancer: one step forward to precise targeting.

Authors:  Hye Jin Kang; Yoo-Kang Kwak; Myungsoo Kim; So Jung Lee
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-30       Impact factor: 4.322

7.  Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study.

Authors:  Rosario Mazzola; Sergio Fersino; Giuseppe Ferrera; Giovanni Targher; Vanessa Figlia; Luca Triggiani; Nadia Pasinetti; Antonio Lo Casto; Ruggero Ruggieri; Stefano Maria Magrini; Filippo Alongi
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

8.  Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum.

Authors:  Taiyang Zuo; Wenli Lin; Fengyong Liu; Jinshun Xu
Journal:  BMC Cancer       Date:  2021-05-06       Impact factor: 4.430

Review 9.  Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?

Authors:  Feng-Ming Spring Kong; Vitali Moiseenko; Jing Zhao; Michael T Milano; Ling Li; Andreas Rimner; Shiva Das; X Allen Li; Moyed Miften; ZhongXing Liao; Mary Martel; Soren M Bentzen; Andrew Jackson; Jimm Grimm; Lawrence B Marks; Ellen Yorke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-26       Impact factor: 8.013

10.  Complete Disappearance of Choroidal Metastasis from Lung Adenocarcinoma Treated with Bevacizumab and Chemotherapy.

Authors:  Hampig Raphael Kourie; Joelle Antoun; Alexandre Schakal; Elie Nasr; Marwan Sahyoun; Joseph Kattan
Journal:  Case Rep Ophthalmol Med       Date:  2015-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.